ents, however the available literature is restricted. Aims: To describe the thrombotic events inside a pediatric MPN cohort. Solutions: We reviewed charts of our pediatric MPN cohort for data all around thrombotic occasions, which incorporated demographic data, variety of thrombotic occasion, blood counts at time of occasion, and mutational standing. All topics are enrolled on an IRB-approved observational study in which consent/assent was obtained. Effects: In the cohort of 42 small children with MPNs, 6 (14.three ) had a thrombotic event. Five subjects have been female, and 5 were adolescents when thrombosis created. Five topics had a JAK2V617F mutation, even though a single was adverse for almost any identified mutation. A single topic had a stroke, one had a cerebral venous sinus thrombosis and pulmonary embolism, and 4 had Budd-Chiari syndrome. Two topics formulated their thrombotic occasions immediately after diagnosis of theirABSTRACT583 of|LPB0125|Traits of Pediatric Oncology Patients with Tumour Thrombus N. Samji; A.F. Fajardo; A.K. Chan; M.D Bhatt McMaster University, Hamilton, Canada Background: IntraVascular tumour extension can be a rare but important complication of pediatric reliable tumours. There is certainly constrained facts relating to qualities and outcomes of pediatric patients with tumour thrombus. Aims: To search at incidence, chance aspects, management, and outcomes of pediatric oncology individuals with tumour thrombus. Methods: A retrospective analysis was performed on sufferers aged 18 years diagnosed with reliable tumours from 2000 2020 at McMaster Nav1.1 Compound Children’s Hospital. Data assortment incorporated: demographics (age, gender, cancer information, staging, pathology report, remedy, outcomes), and tumour thrombus specifics (imaging, anticoagulation use, resolution, recurrence, issues of anticoagulation, thromboembolic phenomena).Success: Of 347 patients recognized with solid tumours, 53 were excluded because of lack of data. 294 have been incorporated: Neuroblastoma (67), Wilms tumour (WT) (40), renal cell carcinoma (2), Hepatoblastoma (15), germ cell tumour (GCT) (24), Ewing sarcoma (26), osteosarcoma (32), rhabdomyosarcoma (32), rhabdoid tumour (4), desmoplastic compact round cell tumour (three), and other (49). α9β1 manufacturer median age was 5.68 years. Tumour thrombus was identified in ten individuals (10/294; 3.4 ), with WT owning the highest incidence (twelve.five ). Vascular involvement included inferior vena cava (IVC) (n = eight), pulmonary vein branches (n = one), sigmoid sinus (n = one), isolated renal vein (n = 1), mixed renal vein and IVC (n = four). One particular patient had one site concerned. All individuals with tumour thrombus have been higher risk or had metastatic disease except in WT (Table one). Anticoagulation was initiated prior to surgical resection in four scenarios (40 ) and post-operatively in three cases (30 ). Progression of thrombus was recognized in a single patient. IVC thrombus recurrence was noted post-operatively in 3 sufferers with WT.TABLE one Traits of sufferers with and devoid of reliable tumour thrombusDisease Neuroblastoma Danger Factors Age (median in years) Male gender Substantial Danger Group Patients with Tumour Thrombus two.47 0/2 (0 ) 2/2 (100 ) Individuals with no Tumour thrombus two.07 36/65 (fifty five.four ) 30/65 (46.2 )End result Deceased On-therapy Remission Relapsed/ProgressionWilms Age (median) Male Gender Metastatic disease1/2 (50 ) 1/2 (50 ) 0/2 (0 ) 1/2 (50 )four.13 3/5 (60 ) 1/5 (twenty )14/65 (21.five ) 5/65 (seven.7 ) 46/65 (70.one ) 11/65 (16.9 )3.09 23/35 (65.seven ) 5/35 (14.three )End result Deceased Remission Relapsed/ProgressionHepatoblastoma Age (median) Male gender High Ri